Literature DB >> 19015253

Interleukin-15 and NK1.1+ cells provide innate protection against acute Salmonella enterica serovar Typhimurium infection in the gut and in systemic tissues.

Ali A Ashkar1, Sarah Reid, Elena F Verdu, Kun Zhang, Brian K Coombes.   

Abstract

Control of bacterial colonization at mucosal surfaces depends on rapid activation of the innate immune system. Interleukin-15 (IL-15) directs the development, maturation, and function of a population of cells positive for NK1.1, such as natural killer (NK) cells, which are critical components of the innate immune defense against several viral and bacterial pathogens. Using IL-15-deficient mice, in vivo depletion of NK1.1(+) cells from wild-type mice, and in vivo overexpression of IL-15 from a recombinant adenovirus, we tested the role of IL-15 and NK1.1(+) cells in innate protection of the murine gut and reticuloendothelial system from Salmonella enterica serovar Typhimurium infection. IL-15 and the NK1.1(+) cell population provided innate protection from serovar Typhimurium in mice at the enteric mucosae and in the reticuloendothelial system during murine typhoid. Interestingly, serovar Typhimurium extensively colonized the gut of IL-15(-/-) mice and wild-type C57BL/6 mice depleted of NK1.1(+) cells prior to infection, even though the animals were not pretreated with antibiotics to reduce colonization resistance and there was an absence of overt inflammation in the colon and cecum. Enhanced dissemination of Salmonella from the gut of mice depleted of NK1.1(+) cells correlated with a localized disruption of IL-17 in the colon. These data suggest a relationship between the gut ecosystem and the innate mucosal immune system, which may be linked via IL-15 and NK1.1(+) cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015253      PMCID: PMC2612292          DOI: 10.1128/IAI.01066-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.

Authors:  Manfred Brigl; Lynn Bry; Sally C Kent; Jenny E Gumperz; Michael B Brenner
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

2.  Memory phenotype CD8(+) T cells in IL-15 transgenic mice are involved in early protection against a primary infection with Listeria monocytogenes.

Authors:  T Yajima; H Nishimura; R Ishimitsu; K Yamamura; T Watase; D H Busch; E G Pamer; H Kuwano; Y Yoshikai
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

3.  Mice lacking interleukin-2 (IL-2)/IL-15 receptor beta chain are susceptible to infection with avirulent Salmonella enterica subsp. enterica serovar choleraesuis but mice lacking IL-2 are resistant.

Authors:  H Nishimura; M Tagaya; H Tsunobuchi; H Suzuki; I Nakashima; Y Yoshikai
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host.

Authors:  Manja Barthel; Siegfried Hapfelmeier; Leticia Quintanilla-Martínez; Marcus Kremer; Manfred Rohde; Michael Hogardt; Klaus Pfeffer; Holger Rüssmann; Wolf-Dietrich Hardt
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.

Authors:  Toshiki Yajima; Hitoshi Nishimura; Worawidh Wajjwalku; Mamoru Harada; Hiroyuki Kuwano; Yasunobu Yoshikai
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

6.  The innate immune response differs in primary and secondary Salmonella infection.

Authors:  Alun C Kirby; Ulf Yrlid; Mary Jo Wick
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

7.  Overexpression of interleukin-15 protects against Escherichia coli-induced shock accompanied by inhibition of tumor necrosis factor-alpha-induced apoptosis.

Authors:  Takashi Hiromatsu; Toshiki Yajima; Tetsuya Matsuguchi; Hitoshi Nishimura; Worawidh Wajjwalku; Toshiyuki Arai; Yuji Nimura; Yasunobu Yoshikai
Journal:  J Infect Dis       Date:  2003-04-15       Impact factor: 5.226

8.  Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium.

Authors:  Morten Helms; Pernille Vastrup; Peter Gerner-Smidt; Kåre Mølbak
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

9.  Th1 and Th1-inducing cytokines in Salmonella infection.

Authors:  Y Mizuno; H Takada; A Nomura; C-H Jin; H Hattori; K Ihara; T Aoki; K Eguchi; T Hara
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

10.  Role of the Salmonella pathogenicity island 1 effector proteins SipA, SopB, SopE, and SopE2 in Salmonella enterica subspecies 1 serovar Typhimurium colitis in streptomycin-pretreated mice.

Authors:  Siegfried Hapfelmeier; Kristin Ehrbar; Bärbel Stecher; Manja Barthel; Marcus Kremer; Wolf-Dietrich Hardt
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more
  19 in total

1.  Antibacterial role for natural killer cells in host defense to Bacillus anthracis.

Authors:  Christine M Gonzales; Courtney B Williams; Veronica E Calderon; Matthew B Huante; Scott T Moen; Vsevolod L Popov; Wallace B Baze; Johnny W Peterson; Janice J Endsley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

Review 2.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

Review 3.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

4.  The role of innate immunity in the host defense against intestinal bacterial pathogens.

Authors:  John Sotolongo; Jose Ruiz; Masayuki Fukata
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

5.  IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.

Authors:  Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

6.  NKR-P1B expression in gut-associated innate lymphoid cells is required for the control of gastrointestinal tract infections.

Authors:  Elias Abou-Samra; Zachary Hickey; Oscar A Aguilar; Michal Scur; Ahmad Bakur Mahmoud; Sergey Pyatibrat; Megan M Tu; Jeffrey Francispillai; Arthur Mortha; James R Carlyle; Mir Munir A Rahim; Andrew P Makrigiannis
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

7.  Contribution of Thy1+ NK cells to protective IFN-γ production during Salmonella typhimurium infections.

Authors:  Andreas Kupz; Timothy A Scott; Gabrielle T Belz; Daniel M Andrews; Marie Greyer; Andrew M Lew; Andrew G Brooks; Mark J Smyth; Roy Curtiss; Sammy Bedoui; Richard A Strugnell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

8.  Natural killer cells in asthma.

Authors:  Khalil Karimi; Paul Forsythe
Journal:  Front Immunol       Date:  2013-06-21       Impact factor: 7.561

9.  Effect of the Salmonella pathogenicity island 2 type III secretion system on Salmonella survival in activated chicken macrophage-like HD11 cells.

Authors:  Amanda L S Wisner; Andrew A Potter; Wolfgang Köster
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

Review 10.  NK cells in mucosal defense against infection.

Authors:  Daria Ivanova; Ryan Krempels; Jennyfer Ryfe; Kaitlyn Weitzman; David Stephenson; Jason P Gigley
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.